

IMEXPHARM CORPORATION

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 05 /TTr-HDQT-IMP

Dong Thap, March 25, 2026

PROPOSAL

Re: Approval of the 2026 Business Target and Plan

To: Esteemed Shareholders of Imexpharm Corporation

- Pursuant to the current Law on Enterprises;
- Pursuant to the Charter on organization and operation of Imexpharm Corporation;
- Pursuant to the Report and assessment of the BOD's performance; and Report on business and financial performance of the Board of Management, key business targets and plan in 2026.

The Board of Directors (BOD) respectfully submits to the Annual General Meeting of Shareholders (AGM) for consideration and approval of the 2026 Business Target and Plan with the following main contents:

I. 2026 Business plan targets


Based on our current capabilities and the 2026 business targets, the BOD proposes the following key performance targets:

No.	Target	Unit	Actual for 2025	Plan 2026	Growth
1	Total Revenue	VND Billion	2.914,3	3.200,0	9,8%
2	Profit before tax	VND Billion	446,2	502,0	12,5%
3	EBITDA	VND Billion	567,2	637,0	12,3%

II. Proposal to the AGM

The BOD respectfully submits this proposal to the AGM for consideration and approval:

1. The 2026 business plan targets as set out in Section I.
2. To authorize the BOD, based on the actual business situation, to adjust the plan (if necessary) and decide on implementation measures to ensure the best interests of the shareholders



Respectfully submitted to the AGM for consideration and approval

ON THE BEHALF OF BOD

CHAIRPERSON


M.S.D.N: 1400384433-C.T.C.P
CÔNG TY CP
DƯỢC PHẨM
IMEXPHARM
TỈNH ĐỒNG THÁP
SUNG MIN WOO


34433-C.T.C.P
TY CP
PHẨM
IARM
G THÁP

